Testosterone replacement therapy commonly raises hematocrit, the percentage of red blood cells in your blood, and in some men that rise crosses into a condition called erythrocytosis or secondary polycythemia. Most professional guidelines set a hematocrit ceiling around 54 percent, above which testosterone therapy should be paused, because thicker blood carries a higher risk of blood clots and cardiovascular events. Regular blood testing, and simple management steps like dose adjustment or blood donation, keep this common side effect from becoming a real problem.
Why Does TRT Raise Hematocrit?
Testosterone stimulates the bone marrow to produce more red blood cells in two main ways. It boosts erythropoietin, the hormone that signals bone marrow to make red cells, and it suppresses hepcidin, a liver hormone that normally limits how much iron is available for red blood cell production (Blood Advances, 2025). With more erythropoietin signal and more iron freed up, the bone marrow simply makes more red blood cells than it did before treatment.
This is a well-understood, expected physiological response to testosterone, not a rare side effect. The question is not whether hematocrit rises on TRT, since it usually does to some degree, but how much it rises and whether that rise crosses a threshold where the added red blood cell mass starts to thicken the blood enough to matter clinically.
How Common Is Testosterone-Induced Erythrocytosis?
The rate depends heavily on how the testosterone is delivered. Short-acting intramuscular injections, meaning testosterone cypionate and enanthate given every one to two weeks, carry the highest incidence of erythrocytosis, approaching 40 percent in some series (Ohlander et al., Sexual Medicine Reviews, 2018). That is because injections create a peak in testosterone levels shortly after the shot, and that supraphysiological peak is what drives the strongest marrow stimulation.
Formulations that keep testosterone levels steadier, such as transdermal gels, patches, subcutaneous pellets, and longer-acting injectable esters, produce meaningfully lower rates of erythrocytosis for a given average testosterone level (Ohlander et al., Sexual Medicine Reviews, 2018). If you are prone to elevated hematocrit, the delivery method you choose is one of the biggest levers you have, often bigger than the total weekly dose.
What Hematocrit Level Is Considered Dangerous?
The Endocrine Society's clinical practice guideline for testosterone therapy recommends checking hematocrit at baseline, again at three to six months, and then annually, and it instructs clinicians to withhold testosterone therapy until hematocrit returns to a safe range whenever it exceeds 54 percent (Endocrine Society, 2018). This 54 percent threshold is the most widely cited cutoff in US clinical practice, though some clinics act earlier, at 50 to 52 percent, particularly in men who already carry cardiovascular risk factors.
That earlier, more cautious threshold has real evidence behind it. A large real-world study using the TriNetX database matched nearly 6,000 men who developed polycythemia (a hematocrit of 52 percent or higher) on testosterone therapy against nearly 6,000 men who did not. Men with polycythemia had a composite rate of major adverse cardiovascular events or venous thromboembolism of 5.15 percent in their first year of therapy, compared with 3.87 percent in men with normal hematocrit, a 35 percent increase in odds overall, including 1.8 times higher odds of heart attack and 1.5 times higher odds of venous thromboembolism (Ory et al., Journal of Urology, 2022). Testosterone therapy itself, in men who never developed polycythemia, was not associated with a higher rate of these events in the same analysis.
Does a High Hematocrit Actually Cause Blood Clots?
The mechanism is straightforward even if the exact risk threshold is still debated: more red blood cells means thicker, more viscous blood, and thicker blood flows less easily and clots more readily (European Journal of Endocrinology, 2025). This is the same underlying concern seen in primary polycythemia vera, a bone marrow disorder where dangerously high red cell counts are a well-established cause of stroke and clotting events, though TRT-induced erythrocytosis tends to be milder and more reversible.
Sleep apnea, smoking, chronic lung disease, obesity, and living at high altitude all independently raise hematocrit and compound the effect of TRT, so men with any of these risk factors need closer monitoring and often benefit from a lower starting dose or a steadier delivery method from day one.
